Fundamental Data for MBRX

METABASIS(NSDQ:MBRX)

Metabasis Therapeutics, Inc. discovers and develops drugs for the treatment of liver diseases and metabolic diseases linked to pathways in the liver. They have established a broad pipeline of internally discovered product candidates using their proprietary technologies, NuMimetic and HepDirect.

# Employees: 52

Address: 11119 North Torrey Pines Road,La Jolla,CA,USA

Phone: 858 587-2770

Fax: 858 458-3504

Website: www.mbasis.com

Email: bienfait@mbasis.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Paul K. Laikind Ph.D. (Presi.; C.E.O.; Sec.; Dir.)

John W. Beck C.P.A (Sr. V.P. Fin.; C.F.O.; Treas.; Princ. Acctg. Off.)

Mark D. Erion Ph.D (Exec. V.P. Res. & Dev.; Dir.; Chief Scientific Off)

William R. Rohn (Dir.)

David F. Hale (Chmn.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 6/30/2009

Next Earnings Date(Expected): 11/20/2009

Mean EPS (Next Qtr): $0.01

Mean EPS (Year): ($0.14)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 1

Shares Performance

Period	MBRX	Compare to S&P
YTD	23.94 %	2.57 %
4 Weeks	-46.40 %	-46.98 %
12 Weeks	-15.62 %	-20.45 %

Shares Information

Analyst Coverage: Y

Avg Volume: 875498

Shares Outstanding: 35M

Market Cap: $0.01B

52 Week High: $0.91

52 Week Low: $0.23

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 MBRX split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: 139.13 %

EPS Growth in Last Year: 126.47 %

Sales Growth in Last Quarter: -49.75 %

Sales Growth in Last Quarter: 248.07 %

Financials

Qtr Book Value: $4.91

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 0.760